Ocugen (OCGN) Q1 2025 Earnings
How Did OCGN Stock React to Q1 2025 Earnings?
S&P 500 over the same 30 days: +6.56%.
Did OCGN Beat Earnings? Q1 2025 Results
Yes. Ocugen reported Q1 2025 earnings of $-0.05 a share on May 9, 2025, beating the $-0.06 consensus estimate by 16.7%. Revenue was $1.5M.
Ocugen posted a narrower-than-expected loss in Q1 2025, offering a modest bright spot for a clinical-stage company navigating a demanding multi-program pipeline. The gene therapy developer reported an EPS loss of $0.05, beating the consensus estimate of $0.06 by 16.67%, while collaborative arrangement revenue climbed 46.1% year-over-year to $1.48 million, clearing a bar analysts had set at zero. The better-than-feared bottom line, however, masked a widening net loss of $15.35 million, driven by a surge in R&D spending to $9.53 million as the company pressed forward on three modifier gene therapy programs simultaneously. Cash declined to $38.10 million from $58.80 million at year-end, with management projecting the runway extends into Q1 2026, underscoring the urgency of securing additional financing or partnerships. Looking ahead, Ocugen is targeting BLA/MAA filings for its lead retinitis pigmentosa program OCU400 by mid-2026, with the OCU410ST pivotal trial for Stargardt disease set to initiate by mid-2025, keeping the company's three-year filing ambitions intact.
- Increased R&D spending driven by advancing multiple clinical programs through Phase 2/3 and Phase 3 trials
- Collaborative arrangement revenue increased to $1.5 million from $1.0 million year-over-year
“All three of our novel modifier gene therapies are advancing through the clinic and we are on track to meet our goal of three Biologics License Application (BLA)/Marketing Authorization Application (MAA) filings in the next three years.”
Ocugen CEO, on the earnings call
What Was Ocugen's Outlook in Q1 2025?
Ocugen expects its cash and restricted cash runway to extend into Q1 2026. The company targets BLA/MAA filings for OCU400 by mid-2026, plans to initiate the OCU410ST Phase 2/3 pivotal trial by mid-2025 with a target BLA filing in 2027, and aims to complete the OCU200 Phase 1 trial in H2 2025. The company aims for three BLA/MAA filings across its modifier gene therapy programs within the next three years. NeoCart Phase 3 initiation is contingent on adequate funding availability and/or a future partnership. NIAID intends to initiate a Phase 1 clinical trial for OCU500 in Q2 2025.
OCGN YoY Financials
| Metric | Q1 2025 | Q1 2024 | Year over year |
|---|---|---|---|
| Revenue | $1.5M | $1.0M | +46.1% |
| Operating Income | −$14.5M | −$17.8M | −18.7% |
| Net Income | −$15.4M | −$21.5M | −28.7% |
OCGN Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.